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Lung transplantation is a well-established treatment for advanced lung diseases. In children, the diseases that
most commonly lead to the need for a transplantation are cystic fibrosis, pulmonary hypertension, and
bronchiolitis. However, the number of pediatric lung transplantations being performed is low compared with
the number of transplants performed in the adult age group. The objective of this study was to demonstrate
our experience with pediatric lung transplants over a 10-year period in a program initially designed for adults.
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& INTRODUCTION
Lung transplantation (LTx) is now a well-established
therapy for treating various chronic lung diseases that lead
to severe respiratory failure. LTx has improved significantly
since it began in 1963 with James Hardy (1). An increasing
number of studies have focused on studying the indications,
techniques, immunosuppressive drugs, and criteria for
donation. The first pediatric LTx occurred in 1987 in a 16-
year-old boy with familial pulmonary fibrosis (2).
The annual number of pediatric lung transplants per-
formed is significantly lower than that of adult transplant
surgeries performed each year. According to a 2013 report
from the International Society of Heart and Lung Trans-
plantation, from 1986 to June 2012, in patients younger than
18 years, 1875 lung transplants and 667 double heart and
lung transplantations were reported (3), whereas there were
3640 transplanted adults in 2011 (4).
The most common indication for LTx in patients up to 18
years old is cystic fibrosis (3), a fact that is also demon-
strated in this study. Other indications for LTx include
bronchiolitis obliterans, bronchiectasis, pulmonary arterial
hypertension, idiopathic fibrosis, interstitial lung diseases,
and surfactant protein abnormalities (5).
The aim of this study was to describe the pediatric lung
transplantation experiences at the Heart Institute (InCor) of
Faculdade de Medicina da Universidade de Sa˜o Paulo.
& PATIENTS AND METHODS
A retrospective analysis of the medical records of patients
undergoing lung transplantation at the Heart Institute
(Incor) of Hospital das Clı´nicas da Faculdade de Medicina
de Sa˜o Paulo was performed for the period from January
2003 to October 2013.
& RESULTS
From February 2003 to October 2013, 192 lung transplants
were performed at our institution (11 patients 18 years
old and younger). The recipient distribution by age and
diagnosis is shown in Figure 1.
All 11 pediatric patients underwent bilateral sequential
LTx; two patients required cardiopulmonary bypass during
surgery. To date, the longest surviving pediatric transplant
patient underwent surgery 5 years ago when he was 11
years old.
Two patients suffered immediate postoperative death
less than one month post transplantation. The first patient,
whose initial diagnosis was idiopathic pulmonary arterial
hypertension, developed primary graft dysfunction and
died on the 4th postoperative day. This patient was six
years old and required cardiopulmonary bypass. The
second patient, a 17-year-old adolescent diagnosed with
bronchiolitis obliterans associated with secondary pulmon-
ary hypertension, also underwent cardiopulmonary bypass;
the patient developed refractory hemodynamic instability
and died three days post-surgery.
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One patient with an initial diagnosis of bronchiectasis
died three years after undergoing transplantation for
chronic graft dysfunction with clinical restrictive syndrome.
A 16-year-old patient with an initial diagnosis of post-
infectious bronchiolitis obliterans syndrome later developed
obliterative bronchiolitis and underwent retransplantation
three years after the initial procedure.
In our institution, induction therapy is performed
with 10 mg/kg intravenous methylprednisolone, with
basiliximab in the case of initial suppurative disease. The
maintenance immunosuppression combines corticosteroids
(prednisone), calcineurin inhibitor (cyclosporine or tacroli-
mus), and a cellular activation inhibitor (azathioprine or
mycophenolate sodium).
The complications related to the immunosuppressive
regimen were infection (in the majority of cases) and rever-
sible posterior leukoencephalopathy (one case) in a patient
initially diagnosed with cystic fibrosis. This patient was on
cyclosporine and showed neurological symptoms eight days
after the procedure, progressing to acute subdural hemor-
rhage. Currently, he has motor neurological deficit without
other complications.
In our study, the most common infection found after the first
month of transplant was due to citomegalovirus (CMV),
followed by respiratory viral infections and bacterial infections.
Figure 2 shows the survival rate based on the time after
transplantation for patients 18 years old and younger.
& DISCUSSION
LTx is a well-established therapy for patients with chronic
lung disease and end-stage vascular pulmonary disease.
Indications for LTx in the pediatric population are rare
because terminal illnesses in this age group are uncommon
(5). Most patients younger than 18 years who undergo lung
transplantation are older than 11 years (3,6), which was also
found in our study group.
The main indications for LTx in the pediatric population
are pulmonary cystic fibrosis, interstitial lung disease
associated with pulmonary fibrosis, and congenital vascular
disease (4,5). Furthermore, in Brazil, the prevalence of
bronchiectasis (not secondary to cystic fibrosis) is consider-
able, and this condition frequently requires LTx.
In the adult population, the main indications are emphy-
sema and idiopathic pulmonary fibrosis (4).
The pediatric contraindications for the procedure are
identical to those in the adult population and include
systemic diseases with extrapulmonary complications, mali-
gnancy, HIV infection, and severe renal impairment. The
absence of social support, transportation issues, or poor
adherence to treatment are also important conditions that
preclude LTx (7).
The number of pediatric transplants performed in our
study group, although small, corresponded to approxi-
mately 5.7% of the total number of transplants performed,
which did not differ from the literature (3). The survival rate
was also similar to that of the international registry, but a
longer follow-up is necessary, as illustrated by the patient
with a longer follow-up who underwent surgery 5 years
earlier.
The low number of donors and viable organs for donation
is a significant complicating factor that has affected the
pediatric and adult LTx program.
As in the adult population, there are three main types
of postoperative complications: immediate complications,
occurring in the first days after transplantation; early com-
plications, occurring within three months posttransplanta-
tion; and late complications (8).
The immediate postoperative complications are hyper-
acute rejection, primary graft dysfunction, reperfusion
injury, and surgical complications, such as anastomotic
dehiscence and bleeding.
Hyperacute rejection is an uncommon condition. Today,
virtual crossmatching performed preoperatively in patients
with a high reactive panel identifies any possible incompat-
ibility that could preclude transplantation between the
recipient and donor. Hyperacute rejection has a poor
prognosis, and treatment should be started immediately
if the prospective crossmatch is positive. The treatment
consists of plasmapheresis in the operating room and
Figure 1 - Distribution of recipients according to age and diagnosis.
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during the postoperative period, with the administration
of intravenous immunoglobulin and thymoglobulin as an
additional potential indication for retransplantation (8,9).
Another important complication is primary graft dysfunc-
tion, which occurred in our setting and can occur within 72
hours post-surgery. Primary graft dysfunction is defined by
a low relationship between PaO2 and FiO2, with or without
radiographic changes. The complication is described in
Table 1. International data show that cardiopulmonary
bypass is used more frequently in pediatric LTx compared
with adult LTx, and its use is related to the development of
primary graft dysfunction, smoking status of the donor,
presence of reperfusion injury, and body mass index of the
recipient (8,10,11). In acute respiratory distress syndrome,
clinical management consists of protective ventilation
and, in some cases, the use of extracorporeal membrane
oxygenation (10,12,13).
Acute rejection, infection, side effects of immunosuppres-
sive drugs, and surgical complications, such as stenosis of
the bronchial anastomosis, are some immediate postopera-
tive complications; they frequently occur in the first three
months after LTx.
Clinically, diagnosing acute rejection and respiratory
infections can be challenging, and they require different
treatments. The diagnosis of acute rejection is made using
histological findings that show perivascular mononuclear
cell infiltrate. The intensity and extent of the acute rejection
determines its classification (14). When indicated, treatment
consists of adjusting the immunosuppression, including
changing or increasing the dose of the immunosuppressive
maintenance regimen, administering high doses of corticos-
teroids (in some cases), and using intravenous thymoglo-
bulin in more severe or refractory cases (15). The infection
treatment is based on etiological agents.
Infections are often related to the use of immunosuppres-
sive drugs, and infections are one type of complication that
can be present during the entire posttransplant follow-
up period. The use of maintenance medications has other
undesirable effects, including metabolic changes (hypergly-
cemia and dyslipidemia) and nephrotoxicity. In our study
group, one patient had reversible posterior leukoence-
phalopathy, a disease that is often associated with the use
of calcineurin inhibitors and that has variable outcomes
(16,17). It involves a wide spectrum of neurological
manifestations, such as a decreased level of consciousness,
seizures, and visual disturbances that are frequently
associated with ischemic changes mainly in parietal and
occipital lesions, as evidenced by MRI. The reversibility of
lesions is case dependent. Patient management usually
consists of reducing or changing the calcineurin inhibitor.
Our case showed reversibility of the changes after the initial
change in the immunosuppressant agent, but the patient
developed hemorrhagic transformation and persistent
motor deficiency.
Bronchiolitis obliterans syndrome is the main late
complication; it corresponds to chronic graft dysfunction.
Bronchiolitis obliterans syndrome is defined by a 20% drop
in the forced expiratory volume (FEV1) value in one second
compared with the patient’s baseline, and it is diagnosed
using the best three FEV1 values previously taken after
the development of fixed airflow obstruction on spirometry
and in the absence other factors that may influence the
collection method (18). The differential diagnosis includes
other causes of FEV1 decline, such as anastomotic stenosis
or respiratory infections. In some cases, the patient may
present with severe dysfunction and end-stage pulmonary
disease, and any indication for retransplantation should be
carefully evaluated (5). In our study group, retransplanta-
tion was indicated three years after the first procedure in a
patient who underwent transplantation at age 16.
The indications for LTx in a pediatric population are
less common than those in an adult population. Certain
Figure 2 - Survival Curve – Kaplan Meier.
Table 1 - Classification of Primary graft dysfunction - Adapted from ISHLT (International Society of Heart and Lung
Transplantation Registries) (10).
Grades PaO2/FiO2 Persistant pulmonary infiltration at radiographic image with pulmonary edema
0 .300 Absence
1 .300 Present
2 200-300 Present
3 ,200 Present
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peculiarities, such as the prevalence of different diseases,
indicate the procedure and direct its perioperative manage-
ment, although the postoperative complications and treat-
ments are similar to those found in patients older than 18. In
our setting, the indications, prevalence of pediatric LTx, and
survival rates were similar to those in the international data,
despite the small number of patients.
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